Drugs / Trimetrexate glucuronate
Trimetrexate glucuronate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NEUTREXIN | — | 1993-12-17 | fda.gov ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00003446 | Dec 1997 → Aug 2005 | colorectal cancer | Grupo Oncologico Cooperativo del Sur | Completed | No outcome recorded |
| Phase 2 | NCT00002738 | Jan 1996 → Jun 2006 | leukemia, lymphoma, sarcoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00002103 | — | HIV infectious disease, pneumocystosis | U.S. Bioscience | Completed | No outcome recorded |
| — | NCT00002317 | — | HIV infectious disease, pneumocystosis | U.S. Bioscience | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimetrexate glucuronate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002317 ↗ |
| Known as | Neutrexin | “A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With...” NCT00002103 ↗ |
| Known as | TMTX | “Patients receive trimetrexate glucuronate (TMTX) IV over 1 hour on day 1.” NCT00003446 ↗ |
| Route | Intravenous | “Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days.” NCT00002103 ↗ |